India, April 13 -- Stephen Furst, the American actor and filmmaker, once said, "The way to deal with the devil of obesity and diabetes is literally one day at a time." In today's world, these two conditions have become increasingly intertwined.
As obesity rates continue to rise, diabetes cases are climbing in tandem. This strong connection between the two epidemics has fueled growing excitement around a particular class of drugs in both obesity and diabetes care.
Yes, you guessed it right - they are the GLP -1 (Glucagon -Like Peptide -1 agonist) drugs.
Although the first drug in this class was approved as early as 2005, it wasn't until 2025 that their transformative impact on weight management and diabetes treatment truly gained widespre...